According to Coherent Market Insights, the global respiratory inhalers market size is estimated to be valued at USD 33.11 billion in 2024 and is expected to surpass USD 49.10 billion by 2031, growing at a CAGR of 5.8% from 2024 to 2031.
Demand in the market is fueled by rising incidence of chronic respiratory diseases such as chronic obstructive pulmonary disease (COPD) and asthma. As per the World Health Organization (WHO) statistics, asthma causes around 250,000 deaths and affects around 235 million people globally every year. The main cause of rising rate of asthma is changing lifestyle and increasing pollution rates.
Request a Sample Copy of the Report @ https://www.coherentmarketinsights.com/insight/request-sample/227
Technological advancements in inhalers such as digital and sensor-based smart inhalers are gaining traction. These smart inhalers help patients track medication use and notify doctors about low adherence levels.
Market Trends
Growing dry powder inhalers (DPIs) demand in comparison to traditional metered dose inhalers (MDIs) will accelerate demand. DPIs don not need any co-ordination of actuation and breathing and they are easy to use. They are also sustainable as they do not contain gases that harm the ozone layer.
Rising demand for reusable inhalers will drive market growth further. These inhalers reduce medical waste and are less costly as compared to disposable inhalers. Manufacturers are working on developing smart reusable inhalers integrated with digital sensors and mobile apps. This provides remote monitoring of patients' medication use by physicians.
Respiratory Inhalers Market Report Coverage
|
Report Coverage |
Details |
|
Market Revenue in 2024 |
$33.11 billion |
|
Estimated Value by 2031 |
$49.10 billion |
|
Growth Rate |
Poised to grow at a CAGR of 5.8% |
|
Historical Data |
2019–2023 |
|
Forecast Period |
2024–2031 |
|
Forecast Units |
Value (USD Million/Billion) |
|
Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
|
Segments Covered |
By Type, By Product, By Application, By End User |
|
Geographies Covered |
North America, Europe, Asia Pacific, and Rest of World |
|
Growth Drivers |
• Increasing Prevalence of Respiratory Diseases • Technological advancements in inhalers |
|
Restraints & Challenges |
• High price of respiratory inhalers • Side effects of inhalers |
Market Opportunities
Manually operated inhalers segment accounted for the largest share of the respiratory inhalers market in 2023, valued at US$ 20 billion. Manually operated inhalers are durable, low cost, and easy to use. They do not require batteries or charges and can store medicine for long periods of time without power. Digitally operated inhalers offer added functionality. It includes dosage tracking and connectivity. Manually operated inhalers remain the standard first-line therapy for treating conditions like asthma and COPD. Their simple design has made them the preferred choice for patients new to inhaler therapy and in developing markets where healthcare access is limited.
Immediate Delivery Available | Buy This Premium Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/227
Dry powdered inhalers’ segment revenue stood at US$ 8 billion in 2023. These inhalers offer patients an option to metered dose inhalers that use propellants. It contain a powdered medicine that patients inhale through the mouthpiece. Recent technological advances have made newer generation dry powdered inhalers easier to use compared to older models. Their lack of propellants also make them more environmentally friendly.
Key Market Takeaways
The respiratory inhalers market sales will expand at 5.8% CAGR from 2024 to 2031. Increasing prevalence of respiratory diseases like COPD and asthma will drive growth. These disease are the result of rising air pollution and smoking rates.
By type, the manually operated segment is likely to take centerstage in the market in 2024. It will hold around 50% market share between 2024 and 2031.
Based on products, dry powdered inhalers segment is expected to dominate the market in 2024. Technological advances make them as effective as metered dose inhalers.
North America will be the leading region and will hold major share over the forecast period. Rising healthcare expenditures and diagnostic rates for respiratory diseases in the region drives demand.
Competitor Insights
- Koninklijke Philips N.V.
- General Electric Healthcare
- ResMed Inc.
- Fisher & Paykel Healthcare
- Medtronic
- Boehringer Ingelhem
- GlaxoSmithKline plc
- AstraZeneca
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
- Mylan N.V.
- Roche Holding AG
- Johnson & Johnson
- Sanofi S.A.
- Merck & Co., Inc.
- Hoffmann-La Roche Ltd.
- Ostuka Pharmaceutical Co., Ltd.
- Cipla Limited.
Recent Developments:
In June 2024, Boehringer Ingelheim launched a new program. This caps out-of-pocket costs at US$ 35 per month for eligible patients using the company’s inhalers.
In April 2024, Teva Pharmaceutcials Industries Ltd. along with Launch Therapeutics Inc., entered into a clinical collaboration. This collaboration is done to advance research of Teva’s ICS-SABA for adult and paediatric asthma purposes.
Ask For Customization @ https://www.coherentmarketinsights.com/insight/request-customization/227
Detailed Segmentation-
By Type
- Manually Operated
- Digitally Operated
By Product
- Dry Powder Inhaler
- Metered Dose Inhaler
- Others
By Application
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
- Arterial Hypertension
- Other
By Region
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Find Most Trending Related Reports:
The global smart inhalers market was valued at US$ 236.1 Mn in 2022 and is forecast to reach a value of US$ 9,357.4 Mn by 2030 at a CAGR of 58.40% between 2023 and 2030.
The Rescue Inhaler Market size is expected to reach US$ 27.9 billion by 2030, from US$ 15.5 billion in 2023, at a CAGR of 8.8% during the forecast period.
The steam inhaler devices market size is expected to reach US$ 4.2 Bn by 2030, from US$ 2.5 Bn in 2023, exhibiting at a CAGR of 7.7% during the forecast period.
Global digital dose inhaler market is estimated to be valued at USD 18.33 Bn in 2024 and is expected to reach USD 64.33 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 19.6% from 2024 to 2031.
About Us:
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact Us:
Mr. Shah
Senior Client Partner – Business Development
Coherent Market Insights
Phone:
US: +1-650-918-5898
UK: +44-020-8133-4027
AUS: +61-2-4786-0457
India: +91-848-285-0837
Email: sales@coherentmarketinsights.com
